1.
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised...
by Dormandy, John A
The Lancet (British edition), 2005, Vol.366 (9493), p.1279-1289
2.
Latent autoimmune diabetes in adults (LADA) should be less latent
by FOURLANOS, S
Diabetologia, 2005, Vol.48 (11), p.2206-2212
3.
Multisystemic Therapy Compared to Telephone Support for Youth with Poorly Controlled Diabetes: Findings from a Randomized Controlled Trial
by Ellis, Deborah A
Annals of behavioral medicine, 2012-05-30, Vol.44 (2), p.207-215
4.
Visfatin Is an Adipokine, But It Is Not Regulated by Thiazolidinediones
by Hammarstedt, Ann
The journal of clinical endocrinology and metabolism, 2006-03, Vol.91 (3), p.1181-1184
5.
The mechanisms of action of metformin
by Rena, Graham
Diabetologia, 2017-08-03, Vol.60 (9), p.1577-1585
6.
PPARγ signaling and metabolism: the good, the bad and the future
by Ahmadian, Maryam
Nature medicine, 2013-05, Vol.19 (5), p.557-566
7.
The influence of glucose-lowering therapies on cancer risk in type 2 diabetes
by Currie, C. J
Diabetologia, 2009-07-02, Vol.52 (9), p.1766-1777
8.
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiori...
by Gallwitz, Baptist, Prof
The Lancet (British edition), 2012, Vol.380 (9840), p.475-483
9.
SGLT2 Inhibitors May Predispose to Ketoacidosis
by Taylor, Simeon I
The journal of clinical endocrinology and metabolism, 2015-08, Vol.100 (8), p.2849-2852
10.
Metformin: historical overview
by Bailey, Clifford J
Diabetologia, 2017-08-03, Vol.60 (9), p.1566-1576
11.
The Impact of Telehome Care on Health Status and Quality of Life Among Patients with Diabetes in a Primary Care Setting in Poland
by Bujnowska-Fedak, Maria Magdalena
Telemedicine journal and e-health, 2011-04-01, Vol.17 (3), p.153-163
12.
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
by Buse, John B, Prof
The Lancet (British edition), 2009, Vol.374 (9683), p.39-47
13.
Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants
by Lu, Y
The Lancet (British edition), 2016-04-09, Vol.387 (10027), p.1513-1530
14.
Type 1 diabetes
by Atkinson, Mark A, Prof
The Lancet (British edition), 2014, Vol.383 (9911), p.69-82
15.
Management of type 2 diabetes: new and future developments in treatment
by Tahrani, Abd A, MD
The Lancet (British edition), 2011, Vol.378 (9786), p.182-197
16.
Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus
by Watts, Nelson B
The journal of clinical endocrinology and metabolism, 2016-01, Vol.101 (1), p.157-166
17.
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
by Russell-Jones, D
Diabetologia, 2009-08-14, Vol.52 (10), p.2046-2055
18.
Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
by Griffin, Simon J
Diabetologia, 2017-08-02, Vol.60 (9), p.1620-1629
19.
Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
by Bilezikian, John P
The journal of clinical endocrinology and metabolism, 2016-01, Vol.101 (1), p.44-51
20.
Long-term Metformin Use and Vitamin B12 Deficiency in the Diabetes Prevention Program Outcomes Study
by Aroda, Vanita R
The journal of clinical endocrinology and metabolism, 2016-04, Vol.101 (4), p.1754-1761
